Skip to main content Back to Top
Advertisement

11/22/2019

23.4% Sodium Chloride Injection

Products Affected - Description

    • 23.4% Sodium Chloride solution for injection, Fresenius Kabi, 200 mL vial, 20 count, NDC 63323-0088-63
    • 23.4% Sodium Chloride solution for injection, Pfizer, 100 mL bulk glass container, 25 count, NDC 00409-1141-02

Reason for the Shortage

    • Fresenius Kabi had 23.4% sodium chloride injection on shortage due to increased demand.
    • Pfizer has 23.4% sodium chloride injection on shortage due to increased demand.

Available Products

    • 23.4% Sodium Chloride solution for injection, Fresenius Kabi, 100 mL 40 count, NDC 63323-0088-61
    • 23.4% Sodium Chloride solution for injection, Fresenius Kabi, 30 mL vial, 25 count, NDC 63323-0187-30

Estimated Resupply Dates

    • Fresenius Kabi has 23.4% sodium chloride 200 mL vials on back order and the company estimates a release date of mid-December 2019.
    • Pfizer has 23.4% sodium chloride 100 mL vials on back order and the company estimates a release date of December 2019.

Updated

Updated November 22, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 10, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins